Sera Labs offers 1,500 recombinant proteins
Including cytokines, growth factors, chemokines, hormones, enzymes and viral antigens
Sera Lab’s recombinant proteins are mainly derived from bacterial systems and also include mammalian, yeast, insect and plant sources. All are rigorously tested to ensure excellent quality and biological activity.
With headquarters and storage in Haywards Heath, West Sussex and a cell culture research facility in France, Sera Lab offers a complete range of animal-based research products from a variety of origins. The company supplies laboratories in more than 30 countries worldwide, either directly or through distributors.
You may also like
Manufacturing
Titan Enterprises develops PFAS-free material options for turbine flowmeters
Read moreTitan Enterprises is evaluating high-performance, PFAS-free polymers for its turbine flowmeter range, aiming to maintain accuracy, durability and reliability while preparing for evolving international regulations
Trending Articles
You may also like
Manufacturing
Titan Enterprises develops PFAS-free material options for turbine flowmeters
Titan Enterprises is evaluating high-performance, PFAS-free polymers for its turbine flowmeter range, aiming to maintain accuracy, durability and reliability while preparing for evolving international regulations
Research & Development
Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target
Collaboration combines cell-free protein synthesis, proprietary nanodisc technology and cryo-electron microscopy (cryo-EM) for high-resolution structural analysis of a G protein-coupled receptor (GPCR)
Research & Development
Evotec secures $2.9m grant to advance stem cell-based drug safety testing
The three-year Gates Foundation grant will support Evotec's human induced pluripotent stem cell platform, helping global health researchers identify potential developmental toxicity risks earlier in drug discovery
Research & Development
TUM develops GNExT platform to identify potential Alzheimer’s drug candidates
The Technical University of Munich has developed a web-based tool that connects genome-wide association study data with biological networks, helping researchers identify disease mechanisms and potential drug repurposing opportunities